• Explore /
  • Poster
  • / Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.

Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.

Abstract Video & Slides Poster

Authors

null

David M. O'Malley

Division of Gynecologic Oncology, Ohio State University, James Cancer Center, Columbus, OH

David M. O'Malley , Bradley J. Monk , Myong Cheol Lim , Jose Fuentes Pradera , Joseph Buscema , Michelle K. Wilson , Rocco De Vivo , Thomas J. Herzog , Flora Zagouri , Amit M. Oza , Olga N. Mikheeva , John Paul Diaz , Alla Sergeevna Lisyanskaya , Robert Morris , Ilan Bruchim , Marcia Craib , Christy Connor , Danny Shih , Keiichi Fujiwara , Rebecca Kristeleit

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03522246

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 5554)

DOI

10.1200/JCO.2024.42.16_suppl.5554

Abstract #

5554

Poster Bd #

425

Abstract Disclosures

Similar Posters

First Author: Lingying Wu

First Author: Reema Anil Patel

First Author: Beihua Kong

First Author: Marcia Hall